Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Influenza

Free Subscription Articles published in Antiviral Res Retrieve available abstracts of 153 articles: HTML format

Single Articles

August 2021
1. ISON MG, Hayden FG, Hay AJ, Gubareva LV, et al
   Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group.
   Antiviral Res. 2021;194:105158.
   PubMed     Abstract available
   
   
   July 2021
2. KASPRZYK R, Spiewla TJ, Smietanski M, Golojuch S, et al
   Identification and evaluation of potential SARS-CoV-2 antiviral agents targeting mRNA cap guanine N7-Methyltransferase.
   Antiviral Res. 2021;193:105142.
   PubMed     Abstract available
   
   
   
3. TOURET F, Driouich JS, Cochin M, Petit PR, et al
   Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2.
   Antiviral Res. 2021;193:105137.
   PubMed     Abstract available
   
   
   
4. GAN ES, Syenina A, Linster M, Ng B, et al
   A mouse model of lethal respiratory dysfunction for SARS-CoV-2 infection.
   Antiviral Res. 2021;193:105138.
   PubMed     Abstract available
   
   
   
5. PARK JH, Kim B, Antigua KJC, Jeong JH, et al
   Baloxavir-oseltamivir combination therapy inhibits the emergence of resistant substitutions in influenza A virus PA gene in a mouse model.
   Antiviral Res. 2021;193:105126.
   PubMed     Abstract available
   
   
   
6. PERSOONS L, Vanderlinden E, Vangeel L, Wang X, et al
   Broad spectrum anti-coronavirus activity of a series of anti-malaria quinoline analogues.
   Antiviral Res. 2021 Jul 1:105127. doi: 10.1016/j.antiviral.2021.105127.
   PubMed     Abstract available
   
   
   June 2021
7. DO TND, Donckers K, Vangeel L, Chatterjee AK, et al
   A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents.
   Antiviral Res. 2021 Jun 26:105122. doi: 10.1016/j.antiviral.2021.105122.
   PubMed     Abstract available
   
   
   
8. KASHYAP T, Murray J, Walker CJ, Chang H, et al
   Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo.
   Antiviral Res. 2021 Jun 19:105115. doi: 10.1016/j.antiviral.2021.105115.
   PubMed     Abstract available
   
   
   May 2021
9. CHONG Y, Kawai N, Tani N, Bando T, et al
   Virological and clinical outcomes in outpatients treated with baloxavir or oseltamivir: A Japanese multicenter study in the 2019-2020 influenza season.
   Antiviral Res. 2021;192:105092.
   PubMed     Abstract available
   
   
   April 2021
10. SVYATCHENKO SV, Goncharova NI, Marchenko VY, Kolosova NP, et al
    An influenza A(H5N8) virus isolated during an outbreak at a poultry farm in Russia in 2017 has an N294S substitution in the neuraminidase and shows reduced susceptibility to oseltamivir.
    Antiviral Res. 2021 Apr 29:105079. doi: 10.1016/j.antiviral.2021.105079.
    PubMed     Abstract available
    
    
    
11. ZHAO J, Guo S, Yi D, Li Q, et al
    A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase.
    Antiviral Res. 2021;190:105078.
    PubMed     Abstract available
    
    
    
12. DU R, Cooper L, Chen Z, Lee H, et al
    Discovery of Chebulagic Acid and Punicalagin as Novel Allosteric Inhibitors of SARS-CoV-2 3CL(pro).
    Antiviral Res. 2021 Apr 16:105075. doi: 10.1016/j.antiviral.2021.105075.
    PubMed     Abstract available
    
    
    March 2021
13. CICCOSANTI F, Di Rienzo M, Romagnoli A, Colavita F, et al
    Proteomic Analysis Identifies the RNA Helicase DDX3X as a Host Target Against SARS-CoV-2 Infection.
    Antiviral Res. 2021 Mar 26:105064. doi: 10.1016/j.antiviral.2021.105064.
    PubMed     Abstract available
    
    
    
14. ROOSENHOFF R, Schutten M, Reed V, Clinch B, et al
    Secondary substitutions in the hemagglutinin and neuraminidase genes associated with neuraminidase inhibitor resistance are rare in the Influenza Resistance Information Study (IRIS).
    Antiviral Res. 2021 Mar 10:105060. doi: 10.1016/j.antiviral.2021.105060.
    PubMed     Abstract available
    
    
    
15. MILANI M, Donalisio M, Bonotto RM, Schneider E, et al
    Combined in silico and in vitro approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors.
    Antiviral Res. 2021 Mar 10:105055. doi: 10.1016/j.antiviral.2021.105055.
    PubMed     Abstract available
    
    
    February 2021
16. PATEL MC, Chesnokov A, Jones J, Mishin VP, et al
    Susceptibility of widely diverse influenza a viruses to PB2 polymerase inhibitor pimodivir.
    Antiviral Res. 2021;188:105035.
    PubMed     Abstract available
    
    
    
17. HIDEKAZU OSADA, Chon I, Phyu WW, Wagatsuma K, et al
    Development of cycling probe based real-time PCR methodology for influenza A viruses possessing the PA/I38T amino acid substitution associated with reduced baloxavir susceptibility.
    Antiviral Res. 2021 Feb 9:105036. doi: 10.1016/j.antiviral.2021.105036.
    PubMed     Abstract available
    
    
    
18. MARTIN R, Li J, Parvangada A, Perry J, et al
    Genetic Conservation of SARS-CoV-2 RNA Replication Complex in Globally Circulating Isolates and Recently Emerged Variants from Humans and Minks Suggests Minimal Pre-Existing Resistance to Remdesivir.
    Antiviral Res. 2021 Feb 4:105033. doi: 10.1016/j.antiviral.2021.105033.
    PubMed     Abstract available
    
    
    January 2021
19. LIU C, Boland S, Scholle MD, Bardiot D, et al
    Dual Inhibition of SARS-CoV-2 and Human Rhinovirus with Protease Inhibitors in Clinical Development.
    Antiviral Res. 2021 Jan 27:105020. doi: 10.1016/j.antiviral.2021.105020.
    PubMed     Abstract available
    
    
    
20. ZHU Q, Zhang Y, Wang L, Yao X, et al
    Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system.
    Antiviral Res. 2021 Jan 11:105015. doi: 10.1016/j.antiviral.2021.105015.
    PubMed     Abstract available
    
    
    
21. DU R, Cheng H, Cui Q, Peet NP, et al
    Identification of a novel inhibitor targeting influenza A virus group 2 hemagglutinins.
    Antiviral Res. 2021;186:105013.
    PubMed     Abstract available
    
    
    November 2020
22. SVENNINGSEN EB, Thyrsted J, Blay-Cadanet J, Liu H, et al
    Ionophore antibiotic X-206 is a potent inhibitor of SARS-CoV-2 infection in vitro.
    Antiviral Res. 2020 Nov 25:104988. doi: 10.1016/j.antiviral.2020.104988.
    PubMed     Abstract available
    
    
    
23. ZHANG Y, Song W, Chen S, Yuan Z, et al
    A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2.
    Antiviral Res. 2020 Nov 17:104974. doi: 10.1016/j.antiviral.2020.104974.
    PubMed     Abstract available
    
    
    
24. HEJDANEK J, Radilova K, Pachl P, Hodek J, et al
    Structural characterization of the interaction between the C-terminal domain of the influenza polymerase PA subunit and an optimized small peptide inhibitor.
    Antiviral Res. 2020 Nov 6:104971. doi: 10.1016/j.antiviral.2020.104971.
    PubMed     Abstract available
    
    
    
25. ZARAKET H, Hurt AC, Clinch B, Barr I, et al
    Burden of influenza B virus infection and considerations for clinical management.
    Antiviral Res. 2020 Nov 4:104970. doi: 10.1016/j.antiviral.2020.104970.
    PubMed     Abstract available
    
    
    October 2020
26. CHOI SW, Shin JS, Park SJ, Jung E, et al
    Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes.
    Antiviral Res. 2020 Oct 19:104955. doi: 10.1016/j.antiviral.2020.104955.
    PubMed     Abstract available
    
    
    September 2020
27. SAITO R, Osada H, Wagatsuma K, Chon I, et al
    Duration of fever and symptoms in children after treatment with baloxavir marboxil and oseltamivir during the 2018-2019 season and detection of variant influenza a viruses with polymerase acidic subunit substitutions.
    Antiviral Res. 2020;183:104951.
    PubMed     Abstract available
    
    
    
28. ZHU Q, Hu H, Liu H, Shen H, et al
    A synthetic STING agonist inhibits the replication of Human Parainfluenza Virus 3 and Rhinovirus 16 through distinct mechanisms.
    Antiviral Res. 2020 Sep 16:104933. doi: 10.1016/j.antiviral.2020.104933.
    PubMed     Abstract available
    
    
    
29. THEERAWATANASIRIKUL S, Kuo CJ, Phecharat N, Chootip J, et al
    Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.
    Antiviral Res. 2020 Sep 7:104927. doi: 10.1016/j.antiviral.2020.104927.
    PubMed     Abstract available
    
    
    
30. GURARD-LEVIN ZA, Liu C, Jekle A, Jaisinghani R, et al
    Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry.
    Antiviral Res. 2020 Sep 4:104924. doi: 10.1016/j.antiviral.2020.104924.
    PubMed     Abstract available
    
    
    August 2020
31. PATEL MC, Mishin VP, De La Cruz JA, Chesnokov A, et al
    Detection of baloxavir resistant influenza A viruses using next generation sequencing and pyrosequencing methods.
    Antiviral Res. 2020 Aug 13:104906. doi: 10.1016/j.antiviral.2020.104906.
    PubMed     Abstract available
    
    
    
32. LI W, Li J, Sun M, Yang L, et al
    Viperin protein inhibits the replication of caprine parainfluenza virus 3 (CPIV 3) by interaction with viral N protein.
    Antiviral Res. 2020 Aug 12:104903. doi: 10.1016/j.antiviral.2020.104903.
    PubMed     Abstract available
    
    
    
33. KONKOLOVA E, Dejmek M, Hrebabecky H, Sala M, et al
    Remdesivir triphosphate can efficiently inhibit the RNA-dependent RNA polymerase from various flaviviruses.
    Antiviral Res. 2020 Aug 4:104899. doi: 10.1016/j.antiviral.2020.104899.
    PubMed     Abstract available
    
    
    
34. MOHR PG, Williams J, Tashiro M, Streltsov VA, et al
    Substitutions at H134 and in the 430-loop region in influenza B neuraminidases can confer reduced susceptibility to multiple neuraminidase inhibitors.
    Antiviral Res. 2020 Aug 1:104895. doi: 10.1016/j.antiviral.2020.104895.
    PubMed     Abstract available
    
    
    
35. BIALY D, Shelton H
    Functional neuraminidase inhibitor resistance motifs in avian influenza A(H5Nx) viruses.
    Antiviral Res. 2020 Aug 1:104886. doi: 10.1016/j.antiviral.2020.104886.
    PubMed     Abstract available
    
    
    July 2020
36. OKAMOTO M, Toyama M, Baba M
    The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro.
    Antiviral Res. 2020 Jul 30:104902. doi: 10.1016/j.antiviral.2020.104902.
    PubMed     Abstract available
    
    
    
37. CONZELMANN C, Gilg A, Gross R, Schutz D, et al
    An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection.
    Antiviral Res. 2020 Jul 29:104882. doi: 10.1016/j.antiviral.2020.104882.
    PubMed     Abstract available
    
    
    
38. CAI W, Wen H, Zhou Q, Wu L, et al
    14-Deoxy-11,12-didehydroandrographolide inhibits apoptosis in influenza A(H5N1) virus-infected human lung epithelial cells via the caspase-9-dependent intrinsic apoptotic pathway which contributes to its antiviral activity.
    Antiviral Res. 2020 Jul 20:104885. doi: 10.1016/j.antiviral.2020.104885.
    PubMed     Abstract available
    
    
    
39. GALLIAN P, Pastorino B, Morel P, Chiaroni J, et al
    Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors.
    Antiviral Res. 2020 Jul 14:104880. doi: 10.1016/j.antiviral.2020.104880.
    PubMed     Abstract available
    
    
    
40. PIZZORNO A, Padey B, Dubois J, Julien T, et al
    In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2.
    Antiviral Res. 2020 Jul 14:104878. doi: 10.1016/j.antiviral.2020.104878.
    PubMed     Abstract available
    
    
    
41. VENISSE N, Peytavin G, Bouchet S, Gagnieu MC, et al
    Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection.
    Antiviral Res. 2020 Jul 10:104866. doi: 10.1016/j.antiviral.2020.104866.
    PubMed     Abstract available
    
    
    
42. PAN X, Zhou P, Fan T, Wu Y, et al
    Immunoglobulin fragment F(ab')2 against RBD potently neutralizes SARS-CoV-2 in vitro.
    Antiviral Res. 2020 Jul 10:104868. doi: 10.1016/j.antiviral.2020.104868.
    PubMed     Abstract available
    
    
    
43. KIM SY, Jin W, Sood A, Montgomery DW, et al
    Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions.
    Antiviral Res. 2020 Jul 9:104873. doi: 10.1016/j.antiviral.2020.104873.
    PubMed     Abstract available
    
    
    
44. SALINAS FM, Nebreda AD, Vazquez L, Gentilini MV, et al
    Imiquimod suppresses respiratory syncytial virus (RSV) replication via PKA pathway and reduces RSV induced-inflammation and viral load in mice lungs.
    Antiviral Res. 2020;179:104817.
    PubMed     Abstract available
    
    
    June 2020
45. MATYUSHENKO V, Kotomina T, Kudryavtsev I, Mezhenskaya D, et al
    Conserved T-cell epitopes of respiratory syncytial virus (RSV) delivered by recombinant live attenuated influenza vaccine viruses efficiently induce RSV-specific lung-localized memory T cells and augment influenza-specific resident memory T-cell respo
    Antiviral Res. 2020 Jun 22:104864. doi: 10.1016/j.antiviral.2020.104864.
    PubMed     Abstract available
    
    
    
46. TAKASHITA E, Abe T, Morita H, Nagata S, et al
    Influenza A(H1N1)pdm09 virus exhibiting reduced susceptibility to baloxavir due to a PA E23K substitution detected from a child without baloxavir treatment.
    Antiviral Res. 2020 Jun 20:104828. doi: 10.1016/j.antiviral.2020.104828.
    PubMed     Abstract available
    
    
    
47. JOCKUSCH S, Tao C, Li X, Anderson TK, et al
    A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19.
    Antiviral Res. 2020;180:104857.
    PubMed     Abstract available
    
    
    
48. TILMANIS D, Koszalka P, Barr IG, Rossignol JF, et al
    Host-targeted Nitazoxanide has a high barrier to resistance but does not reduce the emergence or proliferation of oseltamivir-resistant influenza viruses in vitro or in vivo when used in combination with oseltamivir.
    Antiviral Res. 2020 Jun 13:104851. doi: 10.1016/j.antiviral.2020.104851.
    PubMed     Abstract available
    
    
    
49. SHANNON A, Le NT, Selisko B, Eydoux C, et al
    Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites.
    Antiviral Res. 2020;178:104793.
    PubMed     Abstract available
    
    
    May 2020
50. TAI W, Zhang X, He Y, Jiang S, et al
    Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.
    Antiviral Res. 2020 May 13:104820. doi: 10.1016/j.antiviral.2020.104820.
    PubMed     Abstract available
    
    
    
51. BLOCKUS S, Sake SM, Wetzke M, Grethe C, et al
    Labyrinthopeptins as virolytic inhibitors of respiratory syncytial virus cell entry.
    Antiviral Res. 2020;177:104774.
    PubMed     Abstract available
    
    
    April 2020
52. MANTLO E, Bukreyeva N, Maruyama J, Paessler S, et al
    Antiviral activities of type I interferons to SARS-CoV-2 infection.
    Antiviral Res. 2020;179:104811.
    PubMed     Abstract available
    
    
    
53. ABED Y, Fage C, Checkmahomed L, Venable MC, et al
    Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in mice.
    Antiviral Res. 2020 Apr 25:104807. doi: 10.1016/j.antiviral.2020.104807.
    PubMed     Abstract available
    
    
    
54. BRAY M, Rayner C, Noel F, Jans D, et al
    Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses.
    Antiviral Res. 2020 Apr 21:104805. doi: 10.1016/j.antiviral.2020.104805.
    PubMed    
    
    
    
55. LAURE M, Hamza H, Koch-Heier J, Quernheim M, et al
    Antiviral efficacy against Influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model.
    Antiviral Res. 2020 Apr 15:104806. doi: 10.1016/j.antiviral.2020.104806.
    PubMed     Abstract available
    
    
    
56. SALLARD E, Lescure FX, Yazdanpanah Y, Mentre F, et al
    Type 1 interferons as a potential treatment against COVID-19.
    Antiviral Res. 2020;178:104791.
    PubMed     Abstract available
    
    
    
57. SUZUKI S, Shichinohe S, Itoh Y, Nakayama M, et al
    Low replicative fitness of neuraminidase inhibitor-resistant H7N9 avian influenza A virus with R292K substitution in neuraminidase in cynomolgus macaques compared with I222T substitution.
    Antiviral Res. 2020 Apr 6:104790. doi: 10.1016/j.antiviral.2020.104790.
    PubMed     Abstract available
    
    
    
58. TANG T, Bidon M, Jaimes JA, Whittaker GR, et al
    Coronavirus membrane fusion mechanism offers as a potential target for antiviral development.
    Antiviral Res. 2020 Apr 6:104792. doi: 10.1016/j.antiviral.2020.104792.
    PubMed     Abstract available
    
    
    
59. CALY L, Druce JD, Catton MG, Jans DA, et al
    The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro.
    Antiviral Res. 2020 Apr 3:104787. doi: 10.1016/j.antiviral.2020.104787.
    PubMed     Abstract available
    
    
    
60. CHOY KT, Yin-Lam Wong A, Kaewpreedee P, Sia SF, et al
    Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.
    Antiviral Res. 2020 Apr 3:104786. doi: 10.1016/j.antiviral.2020.104786.
    PubMed     Abstract available
    
    
    March 2020
61. SOLDEVILA N, Toledo D, Ortiz de Lejarazu R, Tamames S, et al
    Effect of antiviral treatment in older patients hospitalized with confirmed influenza.
    Antiviral Res. 2020 Mar 29:104785. doi: 10.1016/j.antiviral.2020.104785.
    PubMed     Abstract available
    
    
    
62. JALILY PH, Duncan MC, Fedida D, Wang J, et al
    Put a cork in it: Plugging the M2 viral ion channel to sink influenza.
    Antiviral Res. 2020 Mar 27:104780. doi: 10.1016/j.antiviral.2020.104780.
    PubMed     Abstract available
    
    
    
63. HUSSEIN AFA, Cheng H, Tundup S, Antanasijevic A, et al
    Identification of entry inhibitors with 4-aminopiperidine scaffold targeting group 1 influenza A virus.
    Antiviral Res. 2020 Mar 25:104782. doi: 10.1016/j.antiviral.2020.104782.
    PubMed     Abstract available
    
    
    
64. SLOAN SE, Szretter KJ, Sundaresh B, Narayan KM, et al
    Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study.
    Antiviral Res. 2020 Mar 6:104763. doi: 10.1016/j.antiviral.2020.104763.
    PubMed     Abstract available
    
    
    
65. TOURET F, de Lamballerie X
    Of chloroquine and COVID-19.
    Antiviral Res. 2020;177:104762.
    PubMed     Abstract available
    
    
    
66. SIGRIST C, Bridge A, Le Mercier P
    A potential role for integrins in host cell entry by SARS-CoV-2.
    Antiviral Res. 2020 Mar 1:104759. doi: 10.1016/j.antiviral.2020.104759.
    PubMed    
    
    
    February 2020
67. QIU H, Andersen H, Tarbet EB, Muhammad FS, et al
    Efficacy of anti-influenza immunoglobulin (FLU-IGIV) in ferrets and mice infected with 2009 pandemic influenza virus.
    Antiviral Res. 2020 Feb 27:104753. doi: 10.1016/j.antiviral.2020.104753.
    PubMed     Abstract available
    
    
    
68. KUMARI R, Guo Z, Kumar A, Wiens M, et al
    Influenza virus NS1- C/EBPbeta gene regulatory complex inhibits RIG-I transcription.
    Antiviral Res. 2020 Feb 21:104747. doi: 10.1016/j.antiviral.2020.104747.
    PubMed     Abstract available
    
    
    
69. MIFSUD EJ, Tilmanis D, Oh DY, Ming-Kay Tai C, et al
    Prophylaxis of ferrets with nitazoxanide and oseltamivir combinations is more effective at reducing the impact of influenza a virus infection compared to oseltamivir monotherapy.
    Antiviral Res. 2020 Feb 20:104751. doi: 10.1016/j.antiviral.2020.104751.
    PubMed     Abstract available
    
    
    January 2020
70. TAKASHITA E, Daniels RS, Fujisaki S, Gregory V, et al
    Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018.
    Antiviral Res. 2020 Jan 28:104718. doi: 10.1016/j.antiviral.2020.104718.
    PubMed     Abstract available
    
    
    November 2019
71. PASCUA PNQ, Marathe BM, Bisen S, Webby RJ, et al
    Influenza B viruses from different genetic backgrounds are variably impaired by neuraminidase inhibitor resistance-associated substitutions.
    Antiviral Res. 2019 Nov 29:104669. doi: 10.1016/j.antiviral.2019.104669.
    PubMed     Abstract available
    
    
    August 2019
72. BAVAGNOLI L, Campanini G, Forte M, Ceccotti G, et al
    Identification of a novel antiviral micro-RNA targeting the NS1 protein of the H1N1 pandemic human influenza virus and a corresponding viral escape mutation.
    Antiviral Res. 2019 Aug 27:104593. doi: 10.1016/j.antiviral.2019.104593.
    PubMed     Abstract available
    
    
    
73. ARIKATA M, Itoh Y, Shichinohe S, Nakayama M, et al
    Efficacy of clarithromycin against H5N1 and H7N9 avian influenza a virus infection in cynomolgus monkeys.
    Antiviral Res. 2019 Aug 14:104591. doi: 10.1016/j.antiviral.2019.104591.
    PubMed     Abstract available
    
    
    July 2019
74. NG K, Raheem J, St Laurent CD, Marcet CT, et al
    Responses of human mast cells and epithelial cells following exposure to influenza A virus.
    Antiviral Res. 2019 Jul 23:104566. doi: 10.1016/j.antiviral.2019.104566.
    PubMed     Abstract available
    
    
    
75. LI J, Yang Y, Wang M, Ren X, et al
    Rapid isolation of a potent human antibody against H7N9 influenza virus from an infected patient.
    Antiviral Res. 2019;170:104564.
    PubMed     Abstract available
    
    
    
76. ABED Y, Fage C, Checkmahomed L, Begin G, et al
    The Val430Ile neuraminidase (NA) substitution, identified in influenza B virus isolates, impacts the catalytic 116Arg residue causing reduced susceptibility to NA inhibitors.
    Antiviral Res. 2019 Jul 16:104561. doi: 10.1016/j.antiviral.2019.104561.
    PubMed     Abstract available
    
    
    
77. SEDEYN K, Saelens X
    New antibody-based prevention and treatment options for influenza.
    Antiviral Res. 2019 Jul 16:104562. doi: 10.1016/j.antiviral.2019.104562.
    PubMed     Abstract available
    
    
    June 2019
78. MIFSUD EJ, Hayden FG, Hurt AC
    Antivirals targeting the polymerase complex of influenza viruses.
    Antiviral Res. 2019 Jun 24:104545. doi: 10.1016/j.antiviral.2019.104545.
    PubMed     Abstract available
    
    
    
79. MCKIMM-BRESCHKIN JL, Barrett S, McKenzie-Kludas C, McAuley J, et al
    Passaging of an influenza A(H1N1)pdm09 virus in a difluoro sialic acid inhibitor selects for a novel, but unfit I106M neuraminidase mutant.
    Antiviral Res. 2019;169:104542.
    PubMed     Abstract available
    
    
    
80. ADAMS SE, Lee N, Lugovtsev VY, Kan A, et al
    Effect of influenza H1N1 neuraminidase V116A and I117V mutations on NA activity and sensitivity to NA inhibitors.
    Antiviral Res. 2019;169:104539.
    PubMed     Abstract available
    
    
    
81. ARTARINI A, Meyer M, Shin YJ, Huber K, et al
    Regulation of influenza a virus mRNA splicing by CLK1.
    Antiviral Res. 2019 Jun 6. pii: S0166-3542(18)30668.
    PubMed     Abstract available
    
    
    May 2019
82. FARRUKEE R, Butler J, Reading PC, Hurt AC, et al
    Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors.
    Antiviral Res. 2019 May 24. pii: S0166-3542(18)30673.
    PubMed     Abstract available
    
    
    
83. GEORGEL AF, Cayet D, Pizzorno A, Rosa-Calatrava M, et al
    Toll-like receptor 5 agonist flagellin reduces Influenza A Virus replication independently of type I interferon and interleukin 22 and improves antiviral efficacy of oseltamivir.
    Antiviral Res. 2019 May 9. pii: S0166-3542(18)30570.
    PubMed     Abstract available
    
    
    
84. KOTOMINA T, Isakova-Sivak I, Matyushenko V, Kim KH, et al
    Recombinant live attenuated influenza vaccine viruses carrying CD8 T-cell epitopes of respiratory syncytial virus protect mice against both pathogens without inflammatory disease.
    Antiviral Res. 2019 May 7. pii: S0166-3542(19)30121.
    PubMed     Abstract available
    
    
    April 2019
85. CHIBANGA VP, Dirr L, Guillon P, El-Deeb IM, et al
    New antiviral approaches for human parainfluenza: Inhibiting the haemagglutinin-neuraminidase.
    Antiviral Res. 2019 Apr 2. pii: S0166-3542(18)30740.
    PubMed     Abstract available
    
    
    
86. TARASOV SA, Zarubaev VV, Gorbunov EA, Sergeeva SA, et al
    Retraction notice to "Activity of ultra-low doses of antibodies to gamma-interferon against lethal influenza A(H1N1)2009 virus infection in mice" [Antiviral Research 93 (2012) 219-224].
    Antiviral Res. 2019;164:177.
    PubMed    
    
    
    March 2019
87. NANNETTI G, Massari S, Mercorelli B, Bertagnin C, et al
    Potent and broad-spectrum cycloheptathiophene-3-carboxamide compounds that target the PA-PB1 interaction of influenza virus RNA polymerase and possess a high barrier to drug resistance.
    Antiviral Res. 2019 Mar 15. pii: S0166-3542(18)30659.
    PubMed     Abstract available
    
    
    February 2019
88. KOSZALKA P, Tilmanis D, Roe M, Vijaykrishna D, et al
    Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018.
    Antiviral Res. 2019 Feb 13. pii: S0166-3542(18)30698.
    PubMed     Abstract available
    
    
    
89. MOHL G, Liddle N, Nygaard J, Dorius A, et al
    Novel influenza inhibitors designed to target PB1 interactions with host importin RanBP5.
    Antiviral Res. 2019 Feb 8. pii: S0166-3542(18)30487.
    PubMed     Abstract available
    
    
    
90. HONG JY, Chen TH, Chen YJ, Liu CC, et al
    Highly immunogenic influenza virus-like particles containing B-cell-activating factor (BAFF) for multi-subtype vaccine development.
    Antiviral Res. 2019;164:12-22.
    PubMed     Abstract available
    
    
    
91. SCHOGLER A, Caliaro O, Brugger M, Oliveira Esteves BI, et al
    Modulation of the unfolded protein response pathway as an antiviral approach in airway epithelial cells.
    Antiviral Res. 2019;162:44-50.
    PubMed     Abstract available
    
    
    January 2019
92. WATANABE A, Ishida T, Hirotsu N, Kawaguchi K, et al
    Baloxavir marboxil in Japanese patients with seasonal influenza: Dose response and virus type/subtype outcomes from a randomized phase 2 study.
    Antiviral Res. 2019;163:75-81.
    PubMed     Abstract available
    
    
    
93. KIM MH, Kang JO, Kim JY, Jung HE, et al
    Single mucosal vaccination targeting nucleoprotein provides broad protection against two lineages of influenza B virus.
    Antiviral Res. 2019 Jan 9. pii: S0166-3542(18)30589.
    PubMed     Abstract available
    
    
    
94. ZHANG K, Li C, Luo YS, Wen L, et al
    Establishment of a lethal aged mouse model of human respiratory syncytial virus infection.
    Antiviral Res. 2019;161:125-133.
    PubMed     Abstract available
    
    
    December 2018
95. GARG R, Latimer L, Gomis S, Gerdts V, et al
    Maternal vaccination with a novel chimeric glycoprotein formulated with a polymer-based adjuvant provides protection from human parainfluenza virus type 3 in newborn lambs.
    Antiviral Res. 2018 Dec 11. pii: S0166-3542(18)30464.
    PubMed     Abstract available
    
    
    October 2018
96. SONG L, Xiong D, Kang X, Jiao Y, et al
    The optimized fusion protein HA1-2-FliC big up tri, openD2D3 promotes mixed Th1/Th2 immune responses to influenza H7N9 with low induction of systemic proinflammatory cytokines in mice.
    Antiviral Res. 2018 Oct 30. pii: S0166-3542(18)30186.
    PubMed     Abstract available
    
    
    
97. NOSHI T, Kitano M, Taniguchi K, Yamamoto A, et al
    In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.
    Antiviral Res. 2018 Oct 11. pii: S0166-3542(18)30363.
    PubMed     Abstract available
    
    
    
98. PICHON M, Picard C, Simon B, Gaymard A, et al
    Clinical management and viral genomic diversity analysis of a child's influenza A(H1N1)pdm09 infection in the context of a severe combined immunodeficiency.
    Antiviral Res. 2018;160:1-9.
    PubMed     Abstract available
    
    
    September 2018
99. ABED Y, Tu V, Carbonneau J, Checkmahomed L, et al
    Comparison of early and recent influenza A(H1N1)pdm09 isolates harboring or not the H275Y neuraminidase mutation, in vitro and in animal models.
    Antiviral Res. 2018 Sep 13. pii: S0166-3542(18)30313.
    PubMed     Abstract available
    
    
    
100. KOLPE A, Schepens B, Ye L, Staeheli P, et al
     Passively transferred M2e-specific monoclonal antibody reduces influenza A virus transmission in mice.
     Antiviral Res. 2018 Sep 1. pii: S0166-3542(18)30314.
     PubMed     Abstract available
     
     
     August 2018
101. XIA C, Seo YJ, Studstill CJ, Vijayan M, et al
     Transient inhibition of sphingosine kinases confers protection to influenza A virus infected mice.
     Antiviral Res. 2018 Aug 17. pii: S0166-3542(18)30220.
     PubMed     Abstract available
     
     
     
102. SOOD R, Kumar N, Bhatia S, Chanu KV, et al
     Neuraminidase inhibitors susceptibility profiles of highly pathogenic influenza A (H5N1) viruses isolated from avian species in India (2006-2015).
     Antiviral Res. 2018 Aug 17. pii: S0166-3542(18)30167.
     PubMed     Abstract available
     
     
     
103. BRODSKAIA AV, Timin AS, Gorshkov AN, Muslimov AR, et al
     Inhibition of influenza A virus by mixed siRNAs, targeting the PA, NP, and NS genes, delivered by hybrid microcarriers.
     Antiviral Res. 2018 Aug 6. pii: S0166-3542(17)30732.
     PubMed     Abstract available
     
     
     July 2018
104. GARG R, Brownlie R, Latimer L, Gerdts V, et al
     A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3.
     Antiviral Res. 2018;158:78-87.
     PubMed     Abstract available
     
     
     
105. SCHRADER T, Dudek SE, Schreiber A, Ehrhardt C, et al
     The clinically approved MEK inhibitor Trametinib efficiently blocks influenza A virus propagation and cytokine expression.
     Antiviral Res. 2018 Jul 7. pii: S0166-3542(18)30364.
     PubMed     Abstract available
     
     
     
106. LACKENBY A, Besselaar TG, Daniels RS, Fry A, et al
     Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017.
     Antiviral Res. 2018;157:38-46.
     PubMed     Abstract available
     
     
     June 2018
107. LA FRAZIA S, Piacentini S, Riccio A, Rossignol JF, et al
     The second-generation thiazolide haloxanide is a potent inhibitor of avian influenza virus replication.
     Antiviral Res. 2018 Jun 13. pii: S0166-3542(18)30079.
     PubMed     Abstract available
     
     
     
108. KO EJ, Lee Y, Lee YT, Kim YJ, et al
     MPL and CpG combination adjuvants promote homologous and heterosubtypic cross protection of inactivated split influenza virus vaccine.
     Antiviral Res. 2018 Jun 6. pii: S0166-3542(18)30007.
     PubMed     Abstract available
     
     
     May 2018
109. CHAUDHURI S, Symons JA, Deval J
     Innovation and trends in the development and approval of antiviral medicines: 1987-2017 and beyond.
     Antiviral Res. 2018 May 11. pii: S0166-3542(18)30180.
     PubMed     Abstract available
     
     
     March 2018
110. MATOS AR, Resende PC, Miranda MD, Garcia CC, et al
     Susceptibility of Brazilian influenza A(H1N1)pdm09 viruses to neuraminidase inhibitors in the 2014-2016 seasons: Identification of strains bearing mutations associated with reduced inhibition profile.
     Antiviral Res. 2018 Mar 27. pii: S0166-3542(17)30768.
     PubMed     Abstract available
     
     
     
111. MCKIMM-BRESCHKIN JL, Barrett S, Wong FYK, Pudjiatmoko, et al
     Identification of Indonesian clade 2.1 highly pathogenic influenza A(H5N1) viruses with N294S and S246N neuraminidase substitutions which further reduce oseltamivir susceptibility.
     Antiviral Res. 2018;153:95-100.
     PubMed     Abstract available
     
     
     
112. MALCOLM BA, Aerts CA, Dubois KJ, Geurts FJ, et al
     PrEP-001 prophylactic effect against rhinovirus and influenza virus - RESULTS of 2 randomized trials.
     Antiviral Res. 2018;153:70-77.
     PubMed     Abstract available
     
     
     
113. MUSHARRAFIEH R, Ma C, Wang J
     Profiling the in vitro drug-resistance mechanism of influenza A viruses towards the AM2-S31N proton channel blockers.
     Antiviral Res. 2018 Mar 5. pii: S0166-3542(18)30065.
     PubMed     Abstract available
     
     
     
114. GU H, Gao Y, Zhou S, Sun F, et al
     Bivalent vaccine platform based on ca influenza virus vaccine elicits protective immunity against human adenoviruses.
     Antiviral Res. 2018 Mar 1. pii: S0166-3542(17)30305.
     PubMed     Abstract available
     
     
     January 2018
115. HUI DS, Lee N, Chan PK, Beigel JH, et al
     The role of adjuvant immunomodulatory agents for treatment of severe influenza.
     Antiviral Res. 2018;150:202-216.
     PubMed     Abstract available
     
     
     October 2017
116. MARATHE BM, Mostafa HH, Vogel P, Pascua PNQ, et al
     A pharmacologically immunosuppressed mouse model for assessing influenza B virus pathogenicity and oseltamivir treatment.
     Antiviral Res. 2017 Oct 31. pii: S0166-3542(17)30491.
     PubMed     Abstract available
     
     
     
117. SARVESTANI ST, McAuley JL
     The role of the NLRP3 inflammasome in regulation of antiviral responses to influenza A virus infection.
     Antiviral Res. 2017 Oct 30. pii: S0166-3542(17)30611.
     PubMed     Abstract available
     
     
     
118. KIM MC, Lee YN, Kim YJ, Choi HJ, et al
     Immunogenicity and efficacy of replication-competent recombinant influenza virus carrying multimeric M2 extracellular domains in a chimeric hemagglutinin conjugate.
     Antiviral Res. 2017;148:43-52.
     PubMed     Abstract available
     
     
     
119. GORDON NA, McGuire KL, Wallentine SK, Mohl GA, et al
     Divalent copper complexes as influenza A M2 inhibitors.
     Antiviral Res. 2017;147:100-106.
     PubMed     Abstract available
     
     
     
120. TILMANIS D, van Baalen C, Oh DY, Rossignol JF, et al
     The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide.
     Antiviral Res. 2017 Oct 3. pii: S0166-3542(17)30546.
     PubMed     Abstract available
     
     
     September 2017
121. WU Y, Yang D, Xu B, Liang W, et al
     Immune efficacy of an adenoviral vector-based swine influenza vaccine against antigenically distinct H1N1 strains in mice.
     Antiviral Res. 2017 Sep 20. pii: S0166-3542(17)30180.
     PubMed     Abstract available
     
     
     August 2017
122. GUBAREVA LV, Besselaar TG, Daniels RS, Fry A, et al
     Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.
     Antiviral Res. 2017 Aug 9. pii: S0166-3542(17)30267.
     PubMed     Abstract available
     
     
     
123. PICHON M, Gaymard A, Josset L, Valette M, et al
     Characterization of oseltamivir-resistant influenza virus populations in immunosuppressed patients using digital-droplet PCR: Comparison with qPCR and next generation sequencing analysis.
     Antiviral Res. 2017 Aug 2. pii: S0166-3542(17)30431.
     PubMed     Abstract available
     
     
     
124. HU Y, Zhang J, Musharrafieh RG, Ma C, et al
     Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses.
     Antiviral Res. 2017;145:103-113.
     PubMed     Abstract available
     
     
     
125. ZHANG S, Sun F, Ren T, Duan Y, et al
     Immunogenicity of an influenza virus-vectored vaccine carrying the hepatitis C virus protein epitopes in mice.
     Antiviral Res. 2017 Aug 1. pii: S0166-3542(16)30742.
     PubMed     Abstract available
     
     
     June 2017
126. PAUL SS, Mok CK, Mak TM, Ng OW, et al
     A cross-clade H5N1 influenza A virus neutralizing monoclonal antibody binds to a novel epitope within the vestigial esterase domain of hemagglutinin.
     Antiviral Res. 2017 Jun 17. pii: S0166-3542(17)30042.
     PubMed     Abstract available
     
     
     
127. LIU M, Lo EC, Wang G, Chow HF, et al
     Identification of influenza polymerase inhibitors targeting polymerase PB2 cap-binding domain through virtual screening.
     Antiviral Res. 2017 Jun 16. pii: S0166-3542(16)30584.
     PubMed     Abstract available
     
     
     
128. PETROVA NV, Emelyanova AG, Gorbunov EA, Edwards MR, et al
     Efficacy of novel antibody-based drugs against rhinovirus infection: In vitro and in vivo results.
     Antiviral Res. 2017;142:185-192.
     PubMed     Abstract available
     
     
     May 2017
129. GIAROLA-SILVA S, Coelho-Dos-Reis JGA, Mourao MM, Campi-Azevedo AC, et al
     Distinct patterns of cellular immune response elicited by influenza non-adjuvanted and AS03-adjuvanted monovalent H1N1(pdm09) vaccine.
     Antiviral Res. 2017;144:70-82.
     PubMed     Abstract available
     
     
     
130. LEE N, Wong CK, Chan MCW, Yeung ESL, et al
     Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: A randomized controlled trial.
     Antiviral Res. 2017 May 20. pii: S0166-3542(17)30141.
     PubMed     Abstract available
     
     
     
131. COURTIN N, Fotso AF, Fautrad P, Mas F, et al
     Antiviral activity of formyl peptide receptor 2 antagonists against influenza viruses.
     Antiviral Res. 2017;143:252-261.
     PubMed     Abstract available
     
     
     April 2017
132. LIU JX, Zhang Y, Hu QP, Li JQ, et al
     Anti-inflammatory effects of rosmarinic acid-4-O-beta-D-glucoside in reducing acute lung injury in mice infected with influenza virus.
     Antiviral Res. 2017 Apr 28. pii: S0166-3542(16)30454.
     PubMed     Abstract available
     
     
     
133. WANG M, Wang S, Wang W, Wang Y, et al
     Inhibition effects of novel polyketide compound PPQ-B against influenza A virus replication by interfering with the cellular EGFR pathway.
     Antiviral Res. 2017;143:74-84.
     PubMed     Abstract available
     
     
     
134. WANG Y, Wu J, Xue C, Wu Z, et al
     A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
     Antiviral Res. 2017 Apr 10. pii: S0166-3542(16)30791.
     PubMed     Abstract available
     
     
     
135. HAASBACH E, Muller C, Ehrhardt C, Schreiber A, et al
     The MEK-inhibitor CI-1040 displays a broad anti-influenza activity in vitro and provides a prolonged treatment window compared to standard of care in vivo.
     Antiviral Res. 2017 Apr 1. pii: S0166-3542(17)30060.
     PubMed     Abstract available
     
     
     
136. YANG JR, Cheng CY, Chen CY, Lin CH, et al
     A virus-like particle vaccination strategy expands its tolerance to H3N2 antigenic drift by enhancing neutralizing antibodies against hemagglutinin stalk.
     Antiviral Res. 2017;140:62-75.
     PubMed     Abstract available
     
     
     
137. ALBULESCU L, Bigay J, Biswas B, Weber-Boyvat M, et al
     Uncovering oxysterol-binding protein (OSBP) as a target of the anti-enteroviral compound TTP-8307.
     Antiviral Res. 2017;140:37-44.
     PubMed     Abstract available
     
     
     March 2017
138. LEYVA-GRADO VH, Palese P
     Aerosol administration increases the efficacy of oseltamivir for the treatment of mice infected with influenza viruses.
     Antiviral Res. 2017;142:12-15.
     PubMed     Abstract available
     
     
     February 2017
139. PENDZIALEK J, Roose K, Smet A, Schepens B, et al
     Bispecific T-Cell engaging antibody constructs targeting a universally conserved part of the viral M2 ectodomain cure and prevent influenza A virus infection.
     Antiviral Res. 2017 Feb 28. pii: S0166-3542(16)30618.
     PubMed     Abstract available
     
     
     
140. GAO L, Han J, Si J, Wang J, et al
     Cryptoporic acid E from Cryptoporus volvatus inhibits influenza virus replication in vitro.
     Antiviral Res. 2017 Feb 20. pii: S0166-3542(16)30540.
     PubMed     Abstract available
     
     
     
141. COLEMAN BL, Hassan K, Green K, Gubbay JB, et al
     Pre-and post-pandemic trends in antiviral use in hospitalized patients with laboratory-confirmed influenza: 2004/05-2013/14, Toronto, Canada.
     Antiviral Res. 2017 Feb 5. pii: S0166-3542(16)30612.
     PubMed     Abstract available
     
     
     
142. TAO W, Hurst B, Shakya AK, Uddin MJ, et al
     Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses.
     Antiviral Res. 2017 Feb 1. pii: S0166-3542(16)30409.
     PubMed     Abstract available
     
     
     January 2017
143. HU Y, Musharrafieh R, Ma C, Zhang J, et al
     An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses.
     Antiviral Res. 2017 Jan 10. pii: S0166-3542(16)30522.
     PubMed     Abstract available
     
     
     
144. TELCIAN AG, Zdrenghea MT, Edwards MR, Laza-Stanca V, et al
     Vitamin D increases the antiviral activity of bronchial epithelial cells in vitro.
     Antiviral Res. 2017;137:93-101.
     PubMed     Abstract available
     
     
     December 2016
145. KOBAYASHI M, Kodama M, Noshi T, Yoshida R, et al
     Therapeutic efficacy of peramivir against H5N1 highly pathogenic avian influenza viruses harboring the neuraminidase H275Y mutation.
     Antiviral Res. 2016 Dec 21. pii: S0166-3542(16)30327.
     PubMed     Abstract available
     
     
     November 2016
146. YANG WT, Yang GL, Wang Q, Huang HB, et al
     Protective efficacy of Fc targeting conserved influenza virus M2e antigen expressed by Lactobacillus plantarum.
     Antiviral Res. 2016 Nov 28. pii: S0166-3542(16)30462.
     PubMed     Abstract available
     
     
     
147. YUAN S, Chu H, Ye J, Singh K, et al
     Identification of a novel small-molecule compound targeting the influenza A virus polymerase PB1-PB2 interface.
     Antiviral Res. 2016 Nov 10. pii: S0166-3542(16)30372.
     PubMed     Abstract available
     
     
     
148. TU V, Abed Y, Barbeau X, Carbonneau J, et al
     The I427T neuraminidase (NA) substitution, located outside the NA active site of an influenza A(H1N1)pdm09 variant with reduced susceptibility to NA inhibitors, alters NA properties and impairs viral fitness.
     Antiviral Res. 2016;137:6-13.
     PubMed     Abstract available
     
     
     October 2016
149. SMEE DF, Barnard DL, Jones SM
     Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice.
     Antiviral Res. 2016 Oct 19. pii: S0166-3542(16)30404.
     PubMed     Abstract available
     
     
     
150. WILSON JR, Guo Z, Reber A, Kamal RP, et al
     An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo.
     Antiviral Res. 2016 Oct 3. pii: S0166-3542(16)30341.
     PubMed     Abstract available
     
     
     February 2016
151. SODERHOLM S, Anastasina M, Islam MM, Tynell J, et al
     Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine.
     Antiviral Res. 2016;126:69-80.
     PubMed     Abstract available
     
     
     
152. LYTRAS T, Kossyvakis A, Mentis A
     NAIplot: An opensource web tool to visualize neuraminidase inhibitor (NAI) phenotypic susceptibility results using kernel density plots.
     Antiviral Res. 2016;126:18-20.
     PubMed     Abstract available
     
     
     
153. YANG JR, Chen CY, Kuo CY, Cheng CY, et al
     A novel H6N1 virus-like particle vaccine induces long-lasting cross-clade antibody immunity against human and avian H6N1 viruses.
     Antiviral Res. 2016;126:8-17.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: